false
0001551152
Common Stock, $0.01 Par Value
ABBV
0001551152
2026-02-24
2026-02-24
0001551152
us-gaap:CommonStockMember
exch:XNYS
2026-02-24
2026-02-24
0001551152
exch:XCHI
us-gaap:CommonStockMember
2026-02-24
2026-02-24
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2026-02-24
2026-02-24
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2026-02-24
2026-02-24
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2026-02-24
2026-02-24
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2026-02-24
2026-02-24
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2026-02-24
2026-02-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): February 24, 2026
ABBVIE
INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-35565 |
|
32-0375147 |
| (State of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
1
North Waukegan Road
North
Chicago, Illinois 60064-6400
(Address
of principal executive offices, including zip code)
(847)
932-7900
(Registrant’s telephone
number, including area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.01 Par Value |
|
ABBV |
|
New
York Stock Exchange
Chicago
Stock Exchange |
| 0.750%
Senior Notes Due 2027 |
|
ABBV27 |
|
New
York Stock Exchange |
| 2.125%
Senior Notes Due 2028 |
|
ABBV28 |
|
New
York Stock Exchange |
| 2.625%
Senior Notes Due 2028 |
|
ABBV28B |
|
New
York Stock Exchange |
| 2.125%
Senior Notes Due 2029 |
|
ABBV29 |
|
New
York Stock Exchange |
| 1.250%
Senior Notes Due 2031 |
|
ABBV31 |
|
New
York Stock Exchange |
| Common Stock, $0.01 Par Value |
ABBV |
Item 8.01. Other Events.
On February 24, 2026, AbbVie Inc. (“AbbVie”)
entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, BofA Securities,
Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, acting for themselves and as representatives of the several underwriters
named in Schedule II therein (collectively, the “Underwriters”), pursuant to which AbbVie agreed to issue and sell
to the Underwriters $750,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”),
$1,500,000,000 aggregate principal amount of its 3.775% senior notes due 2028 (the “2028 Notes”), $1,250,000,000 aggregate
principal amount of its 4.125% senior notes due 2031 (the “2031 Notes”), $1,250,000,000 aggregate principal amount
of its 4.400% senior notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of its 4.750% senior
notes due 2036 (the “2036 Notes”), $1,250,000,000 aggregate principal amount of its 5.550% senior notes due 2056 (the
“2056 Notes”) and $500,000,000 aggregate principal amount of its 5.650% senior notes due 2066 (the “2066 Notes”
and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2056 Notes, the “Notes”).
The price to the public was 100.000% of the principal
amount for the Floating Rate Notes, 99.966% of the principal amount for the 2028 Notes, 99.972% of the principal amount for the 2031 Notes,
99.861% of the principal amount for the 2033 Notes, 99.911% of the principal amount for the 2036 Notes, 99.736% of the principal amount
for the 2056 Notes and 99.714% of the principal amount for the 2066 Notes.
The offering of each series of Notes has been registered
under the Securities Act of 1933, as amended (the “Act”), pursuant to AbbVie’s registration statement on Form
S-3ASR (File No. 333-284980) (the “Registration Statement”) dated as of February 14, 2025. The terms of the Notes
are further described in AbbVie’s preliminary prospectus supplement dated February 24, 2026, as filed with the Securities and Exchange
Commission (the “SEC”) on February 24, 2026 and final prospectus supplement dated February 24, 2026, filed with the SEC on February 26, 2026 (the “Prospectus Supplement”). The closing of the sale of the Notes is expected
to occur on March 4, 2026, subject to customary closing conditions.
The net proceeds from the sale of the Notes, after
deducting the underwriting discounts and estimated offering expenses, are expected to be approximately $7.95 billion. AbbVie intends to use
these net proceeds to repay amounts outstanding under its $4.0 billion 364-Day delayed draw term loan facility that matures in May 2026,
of which $2.0 billion is currently outstanding, and for general corporate purposes which may include the repayment or repurchase of outstanding debt.
The
Underwriting Agreement includes customary representations, warranties and covenants by AbbVie. It also provides for customary indemnification
by each of AbbVie and the respective Underwriters against certain liabilities arising out of or in connection with sale of the Notes and
for customary contribution provisions in respect of those liabilities.
As
more fully described under the caption “Underwriting (Conflicts of Interest)” in the Prospectus Supplement, some of
the underwriters in respect of the Underwriting Agreement and/or their affiliates have in the past performed, and may in the future from
time to time perform, investment banking, financial advisory, lending and/or commercial banking services, or other services for AbbVie
and its subsidiaries, for which they have received, and may in the future receive, customary compensation and expense reimbursement.
Please refer to the Prospectus Supplement for additional
information regarding the offering of the Notes and the terms and conditions of the Notes. The foregoing summary of the Notes does not
purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is attached
as Exhibit 1.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is provided as part of this
Form 8-K:
| 1.1 |
Underwriting Agreement, dated February 24, 2026, by and among AbbVie Inc., J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC (acting for themselves and as representatives of the several underwriters named therein). |
| |
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Forward Looking Statements
Some statements in this Current Report on Form
8-K and the documents incorporated by reference into this Current Report on Form 8-K are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). The words “believe,” “expect,”
“anticipate,” “project” and similar expressions and uses of future or conditional verbs generally identify “forward
looking statements,” which speak only as of the date the statements were made. The matters discussed in these forward-looking statements
are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied
in the forward-looking statements. Where, in any forward looking statement, an expectation or belief as to future results or events is
expressed or implied, such expectation or belief is based on the current plans and expectations of AbbVie management, and expressed in
good faith, and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved
or accomplished. Factors that could cause actual results or events to differ materially from those anticipated include, but are not limited
to, the matters described under Item 1A, “Risk Factors,” and Item 7, “Management’s Discussion and Analysis of
Financial Condition and Results of Operations,” in AbbVie’s Annual Report on Form 10-K for the year ended December 31, 2025,
which has been filed with the SEC. AbbVie notes these factors for investors as permitted by the PSLRA. AbbVie does not undertake, and
specifically declines, any obligation to update the forward-looking statements included in this Current Report on Form 8-K to reflect
events or circumstances after the date hereof, unless AbbVie is required by applicable securities law to do so.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ABBVIE INC. |
| |
|
|
| Date: February 26, 2026 |
By: |
/s/
Scott T. Reents |
| |
|
Scott T. Reents |
| |
|
Executive Vice President, Chief Financial Officer |
